NCT03331198 2026-03-04
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Juno Therapeutics, a Subsidiary of Celgene
Phase 1/2 Recruiting
Clinical Trials
18 trialsNCT03960840 2026-01-09
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Phase 1/2 Active not recruiting
NCT03790332 2025-10-21
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
Pharmacyclics LLC.
Phase 1/2 Completed
NCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT02329847 2025-05-25
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT04494503 2025-04-16
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Ascentage Pharma Group Inc.
Phase 1/2 Recruiting
NCT03379428 2024-12-06
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
US Oncology Research
Phase 1/2 Active not recruiting
NCT03310619 2024-04-04
PLATFORM
Celgene
Phase 1/2 Completed
NCT03684694 2024-02-06
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
ADC Therapeutics S.A.
Phase 1/2 Terminated
NCT02599324 2023-11-18
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Pharmacyclics LLC.
Phase 1/2 Completed
NCT02077166 2022-02-04
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Pharmacyclics LLC.
Phase 1/2 Completed
NCT02406742 2021-09-20
ENHANCE
Celgene
Phase 1/2 Completed
NCT02548962 2019-11-21
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Pharmacyclics LLC.
Phase 1/2 Terminated
NCT02195869 2019-07-11
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
Pharmacyclics LLC.
Phase 1/2 Completed
NCT02142049 2019-02-05
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Pharmacyclics LLC.
Phase 1/2 Completed
NCT02403271 2019-01-03
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Pharmacyclics LLC.
Phase 1/2 Completed
NCT01217749 2015-06-25
PCYC-1109-CA
Pharmacyclics LLC.
Phase 1/2 Completed
NCT01105247 2014-03-31
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
Pharmacyclics LLC.
Phase 1/2 Completed